ARVONews Fall 2016


basic chemistry to physics to epidemiology to ophthalmic surgery — in order to bring together research that has a high probability of advancing the way we understand and/or treat vision- threatening diseases. In addition, in 2017, we are planning to publish quarterly mini-reviews on the following topics: Use of CRISPR to Modify Human Genes, Reversal of Cone Dormancy in Retinitis Pigmentosa, Bench to Bedside Research to Develop a Treatment for Leber Hereditary Optic Neuropathy and Experimental Animal Models of Retinal Dystrophies and Functional Assessments. Submissions to TVST continue to increase rapidly (the annualized submission rate in 2016 has increased by 38% over 2015) and the acceptance rate currently is about 50%. Indexing in the SCIE is the newest benefit to authors, and we anticipate additional index coverage in 2017. Thank you all again for your support of TVST . We will continue to strive to serve you and to enable you to share the results of your work with the scientific community.

Journals, continued from page 23

Translational Vision Science and Technology by Marco Zarbin, MD, PhD, FARVO, Editor-in-chief Translational Vision Science and Technology (TVST) has been accepted for coverage in the Science Citation Index Expanded (SCIE), one of Thomson Reuters’ Impact Factor databases. It will be cross-indexed in their Biological Abstracts and BIOSIS Previews products as well. We thank all of the scientists who have contributed their work to TVST and to the associate editors, editorial board members and reviewers who have enabled us to achieve this milestone. As most ARVO members know, TVST emphasizes multidisciplinary research that bridges the gap between basic research and clinical care. Because of its translational emphasis, TVST publishes manuscripts by scientists and clinicians with very diverse backgrounds — from | ARVONews Fall 2016 | 24

Made with